Tags

Type your tag names separated by a space and hit enter

Differential structural features in soleus and gastrocnemius of carnitine-treated cancer cachectic rats.
J Cell Physiol. 2020 01; 235(1):526-537.JC

Abstract

Muscle wasting is associated with chronic diseases and cancer. Elucidation of the biological mechanism involved in the process of muscle mass loss and cachexia may help identify therapeutic targets. We hypothesized that l-carnitine treatment may differentially revert muscle fiber atrophy and other structural alterations in slow- and fast-twitch limb muscles of rats bearing the Yoshida ascites hepatoma. In soleus and gastrocnemius of tumor-bearing rats (108 AH-130 Yoshida ascites hepatoma cells inoculated intraperitoneally) with and without treatment with l-carnitine (1 g/kg body weight for 7 days, intragastric), food intake, body and muscle weights, fiber typing and morphometry, morphological features, redox balance, autophagy and proteolytic, and signaling markers were explored. Levels of carnitine palmitoyl transferase were also measured in all the study muscles. l-Carnitine treatment ameliorated the atrophy of both slow- and fast-twitch fibers (gastrocnemius particularly), muscle structural alterations (both muscles), and attenuated oxidative stress, proteolytic and signaling markers (gastrocnemius). Despite that carnitine palmitoyl transferase-1 levels increased in both muscle types in a similar fashion, l-carnitine ameliorated muscle atrophy and proteolysis in a muscle-specific manner in cancer-induced cachexia. These data reveal the need to study muscles of different fiber type composition and function to better understand whereby l-carnitine exerts its beneficial effects on the myofibers in muscle wasting processes. These findings also have potential clinical implications, since combinations of various exercise and muscle training modalities with l-carnitine should be specifically targeted for the muscle groups to be trained.

Authors+Show Affiliations

Departament de Bioquímica i Biomedicina Molecular, Cancer Research Group, Facultat de Biologia, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, Barcelona, Spain.Pulmonology Department-Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer Research Group, IMIM-Hospital del Mar, Parc de Salut Mar, Health and Experimental Sciences Department (CEXS), Universitat Pompeu Fabra (UPF), Barcelona Biomedical Research Park (PRBB), Barcelona, and Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.Pulmonology Department-Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer Research Group, IMIM-Hospital del Mar, Parc de Salut Mar, Health and Experimental Sciences Department (CEXS), Universitat Pompeu Fabra (UPF), Barcelona Biomedical Research Park (PRBB), Barcelona, and Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.Departament de Bioquímica i Biomedicina Molecular, Cancer Research Group, Facultat de Biologia, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, Barcelona, Spain.Department of Medical Sciences and Public Health "M. Aresu,", University of Cagliari, Cagliari, Italy.Pulmonology Department-Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer Research Group, IMIM-Hospital del Mar, Parc de Salut Mar, Health and Experimental Sciences Department (CEXS), Universitat Pompeu Fabra (UPF), Barcelona Biomedical Research Park (PRBB), Barcelona, and Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.Departament de Bioquímica i Biomedicina Molecular, Cancer Research Group, Facultat de Biologia, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, Barcelona, Spain.Pulmonology Department-Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer Research Group, IMIM-Hospital del Mar, Parc de Salut Mar, Health and Experimental Sciences Department (CEXS), Universitat Pompeu Fabra (UPF), Barcelona Biomedical Research Park (PRBB), Barcelona, and Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31241186

Citation

Busquets, Sílvia, et al. "Differential Structural Features in Soleus and Gastrocnemius of Carnitine-treated Cancer Cachectic Rats." Journal of Cellular Physiology, vol. 235, no. 1, 2020, pp. 526-537.
Busquets S, Pérez-Peiró M, Salazar-Degracia A, et al. Differential structural features in soleus and gastrocnemius of carnitine-treated cancer cachectic rats. J Cell Physiol. 2020;235(1):526-537.
Busquets, S., Pérez-Peiró, M., Salazar-Degracia, A., Argilés, J. M., Serpe, R., Rojano-Toimil, A., López-Soriano, F. J., & Barreiro, E. (2020). Differential structural features in soleus and gastrocnemius of carnitine-treated cancer cachectic rats. Journal of Cellular Physiology, 235(1), 526-537. https://doi.org/10.1002/jcp.28992
Busquets S, et al. Differential Structural Features in Soleus and Gastrocnemius of Carnitine-treated Cancer Cachectic Rats. J Cell Physiol. 2020;235(1):526-537. PubMed PMID: 31241186.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Differential structural features in soleus and gastrocnemius of carnitine-treated cancer cachectic rats. AU - Busquets,Sílvia, AU - Pérez-Peiró,Maria, AU - Salazar-Degracia,Anna, AU - Argilés,Josep M, AU - Serpe,Roberto, AU - Rojano-Toimil,Alba, AU - López-Soriano,Francisco J, AU - Barreiro,Esther, Y1 - 2019/06/26/ PY - 2018/12/11/received PY - 2019/05/31/accepted PY - 2019/6/27/pubmed PY - 2020/8/26/medline PY - 2019/6/27/entrez KW - experimental cancer-induced cachexia KW - l-carnitine KW - muscle fiber type and morphometry KW - muscle structure and morphology KW - proteolytic, autophagy, and signaling markers KW - slow- and fast-twitch muscles SP - 526 EP - 537 JF - Journal of cellular physiology JO - J Cell Physiol VL - 235 IS - 1 N2 - Muscle wasting is associated with chronic diseases and cancer. Elucidation of the biological mechanism involved in the process of muscle mass loss and cachexia may help identify therapeutic targets. We hypothesized that l-carnitine treatment may differentially revert muscle fiber atrophy and other structural alterations in slow- and fast-twitch limb muscles of rats bearing the Yoshida ascites hepatoma. In soleus and gastrocnemius of tumor-bearing rats (108 AH-130 Yoshida ascites hepatoma cells inoculated intraperitoneally) with and without treatment with l-carnitine (1 g/kg body weight for 7 days, intragastric), food intake, body and muscle weights, fiber typing and morphometry, morphological features, redox balance, autophagy and proteolytic, and signaling markers were explored. Levels of carnitine palmitoyl transferase were also measured in all the study muscles. l-Carnitine treatment ameliorated the atrophy of both slow- and fast-twitch fibers (gastrocnemius particularly), muscle structural alterations (both muscles), and attenuated oxidative stress, proteolytic and signaling markers (gastrocnemius). Despite that carnitine palmitoyl transferase-1 levels increased in both muscle types in a similar fashion, l-carnitine ameliorated muscle atrophy and proteolysis in a muscle-specific manner in cancer-induced cachexia. These data reveal the need to study muscles of different fiber type composition and function to better understand whereby l-carnitine exerts its beneficial effects on the myofibers in muscle wasting processes. These findings also have potential clinical implications, since combinations of various exercise and muscle training modalities with l-carnitine should be specifically targeted for the muscle groups to be trained. SN - 1097-4652 UR - https://www.unboundmedicine.com/medline/citation/31241186/Differential_structural_features_in_soleus_and_gastrocnemius_of_carnitine_treated_cancer_cachectic_rats_ L2 - https://doi.org/10.1002/jcp.28992 DB - PRIME DP - Unbound Medicine ER -